Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria: Male or female,ages18-60. Patients who met criteria for the diagnosis of RA Patients who were signed the informed consent form. Exclusion Criteria: Patients with Malignant tumours, Patients with Infectious diseases, Patients with Hematologic diseases. Patients with other rheumatic diseases. Women who are pregnant or breastfeeding. Hypersensitivity to dietary supplement used in this study. Hypertensive patients
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
"apigenin" and "glycyrrhizin"
"boswellic acid" and "glycyrrhizin"
"placebo"
Patients will receive one capsule contains 10 mg of apigenin (Matricaria chamomilla L extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
Patients will receive one capsule contains 200 mg boswellic acid (Boswellia serrata extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
Patients will receive daily two capsules contain placebo for 6 months